NASDAQ:INVA Innoviva Q4 2025 Earnings Results & Report $18.78 -0.30 (-1.57%) As of 03:26 PM Eastern This is a fair market value price provided by Massive. Learn more. Innoviva beat analyst expectations on both earnings and revenue in its Q4 2025 results, released February 25, 2026. The company reported EPS of $1.94 versus the $0.34 consensus estimate, while revenue of $114.61 million topped the $102.62 million estimate by $11.99 million. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ4 2025Report DateFebruary 25, 2026TimeBefore Market OpensConference Call7:00 AM ET Innoviva EPS ResultsActual EPS$1.94Consensus EPS $0.34Beat/MissBeat by +$1.60One Year Ago EPSN/AEPS Beat Rate4 of last 6 quartersInnoviva Revenue ResultsActual Revenue$114.61 millionExpected Revenue$102.62 millionBeat/MissBeat by +$11.99 millionYoY Revenue GrowthN/AConference Call ResourcesPress Release (8-K)Annual Report (10-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Annual report(10-K) Innoviva Q4 2025 Earnings FAQ Did Innoviva beat earnings estimates for Q4 2025? Innoviva (NASDAQ:INVA) reported earnings of $1.94 per share for Q4 2025, beating the consensus estimate of $0.34. The report was announced on Wednesday, February 25, 2026. What was Innoviva's revenue for Q4 2025? Innoviva reported revenue of $114.61 million for Q4 2025, against a consensus estimate of $102.62 million. Innoviva Earnings HeadlinesInnoviva, Inc. (NASDAQ:INVA) Stock Rated "Moderate Buy" by Wall Street BrokeragesNovember 9 at 2:59 AM | americanbankingnews.comInnoviva (NASDAQ:INVA) Price Target Cut to $34.00 by Analysts at OppenheimerNovember 6, 2026 | americanbankingnews.comYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing.November 11 at 1:00 AM | Profits Run (Ad)Oppenheimer Trims Price Target on Innoviva to $34 From $35, Keeps Outperform RatingNovember 5, 2026 | marketscreener.comMInnoviva, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026November 4, 2026 | marketscreener.comMInnoviva Reports Third Quarter 2026 Financial Results; Highlights Recent Company ProgressNovember 4, 2026 | businesswire.comSee More Innoviva Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Innoviva? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Innoviva and other key companies, straight to your email. Email Address About InnovivaInnoviva (NASDAQ:INVA) is a biopharmaceutical company with two main areas of activity: royalty interests in respiratory medicines developed with GSK and the development and commercialization of specialty medicines. Its respiratory-related royalties include products such as Trelegy Ellipta, Anoro Ellipta and Breo Ellipta, which are used to treat chronic obstructive pulmonary disease and asthma and are marketed by GSK. Through its specialty therapeutics operations, Innoviva focuses on medicines for serious infections and other acute-care conditions. Its portfolio includes products such as Xenleta and Xacduro for certain bacterial infections, Xerava for complicated intra-abdominal infections, and Giapreza for dangerously low blood pressure in adults with septic or other distributive shock. The company was formerly known as Theravance, Inc. and adopted the Innoviva name in 2015, following the separation of Theravance Biopharma. Innoviva’s products and royalty arrangements give it a presence in markets beyond the United States, though the geographic reach varies by product and commercial partner.View Innoviva ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Can Constellation Energy's Contracts Power a Stock Rebound?IonQ Raised the Bar, But 3 Quantum Rivals Face Tough QuestionsAmazon's Rally Is Outpacing Big Tech, But Can AWS Justify the AI Spending?Aehr Test Systems Notches Another Post-Earnings Win as Sales Triple on AI DemandThe Trade Desk Beats on Revenue, But the Fine Print MattersWhy Kinder Morgan's Chairman Just Bought $15 Million in StockA $4 Billion Jolt: NRG Energy Powers Data Center Ambitions Upcoming Earnings Brookfield (11/12/2026)NU (11/12/2026)Applied Materials (11/12/2026)Cisco Systems (11/12/2026)Mizuho Financial Group (11/13/2026)Mitsubishi UFJ Financial Group (11/13/2026)Sumitomo Mitsui Financial Group (11/13/2026)Home Depot (11/17/2026)Walt Disney (11/17/2026)NVIDIA (11/17/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
